The Federal Trade Commission today announced a proposed consent order settling charges that Watson Pharmaceuticals, Inc.’s acquisition of Robin Hood Holdings Limited, owner of Arrow Pharmaceuticals, would have harmed consumers by eliminating future competition for important generic drugs used to treat Parkinson’s disease (cabergoline) and the side effects of chemotherapy (dronabinol). The Commission’s order requires […]
Tag Archives: Health Care Prescription Drugs Competition
FTC Order Prevents Anticompetitive Effects from Pfizers Acquisition of Wyeth
The Federal Trade Commission today announced a settlement resolving its extensive investigation of Pfizer Inc.’s proposed $68 billion acquisition of Wyeth and requiring significant divestitures to preserve competition in multiple U.S. markets for animal pharmaceuticals and vaccines. The proposed consent order remedies the anticompetitive effects the Commission believes are likely to result from the transaction […]
FTC Authorizes Suit To Stop CSLs Proposed $3.1 Billion Acquisition of Talecris Biotherapeutics
The Federal Trade Commission has authorized a lawsuit to block CSL Limited’s proposed $3.1 billion acquisition of Talecris Biotherapeutics Holdings Corporation, charging that the deal would be illegal and would substantially reduce competition in the U.S. markets for four plasma-derivative protein therapies – Immune globulin (Ig), Albumin, Rho-D, and Alpha-1. These therapies are used to […]
FTC Intervenes in King Pharmaceuticals Acquisition of Rival Alpharma Inc.
The Federal Trade Commission has issued a consent order to settle its charges that King Pharmaceuticals, Inc.’s proposed $1.6 billion acquisition of rival drug-maker Alpharma Inc. would be anticompetitive and would violate federal law. The proposed consent order requires King to divest the rights to Alpharma’s branded oral long-acting opioid (LAO) analgesic drug Kadian to […]
FTC Intervenes in King Pharmaceuticals Acquisition of Rival Alpharma Inc.
The Federal Trade Commission has issued a consent order to settle its charges that King Pharmaceuticals, Inc.’s proposed $1.6 billion acquisition of rival drug-maker Alpharma Inc. would be anticompetitive and would violate federal law. The proposed consent order requires King to divest the rights to Alpharma’s branded oral long-acting opioid (LAO) analgesic drug Kadian to […]
FTC Intervenes in Teva Pharmaceutical Industries’ Proposed $8.9 Billion Acquisition of Barr Pharmaceuticals
Teva Pharmaceuticals Industries Ltd.’s has settled Federal Trade Commission charges that its proposed $8.9 billion acquisition of rival generic drugmaker Barr Pharmaceuticals Inc. would be anticompetitive and violate federal law. The consent order requires Teva and Barr to sell assets in 29 U.S. markets, including generic drugs commonly used to treat acid reflux disease, various […]
FTC Sues Ovation Pharmaceuticals for Illegally Acquiring Drug Used to Treat Premature Babies with Life-Threatening Heart Condition
The Federal Trade Commission today filed a complaint in federal district court challenging Ovation Pharmaceuticals, Inc.’s January 2006 acquisition of the drug NeoProfen, which eliminated its only competitor for the treatment of a serious and potentially deadly congenital heart defect affecting more than 30,000 babies born prematurely each year in the United States. When it […]
FTC Sues Ovation Pharmaceuticals for Illegally Acquiring Drug Used to Treat Premature Babies with Life-Threatening Heart Condition
The Federal Trade Commission today filed a complaint in federal district court challenging Ovation Pharmaceuticals, Inc.’s January 2006 acquisition of the drug NeoProfen, which eliminated its only competitor for the treatment of a serious and potentially deadly congenital heart defect affecting more than 30,000 babies born prematurely each year in the United States. When it […]
Commission Approves Final Consent Order in Matter of Fresenius Medical Care AG & Co. KGaA/Daiichi Sankyo Company, Ltd.
Following a public comment period, the Commission has approved a final consent order in the matter concerning Fresenius Medical Care AG & Co. KGaA/Daiichi Sankyo Company, Ltd. The vote approving the final order was 4-0. (FTC File No. 081-0146; the staff contact is Elizabeth A. Jex, Bureau of Competition, 202-326-3273; see press release dated September […]
FTC Challenges Vertical Agreement Between Fresenius and Daiichi Sankyo
The Federal Trade Commission today announced a complaint challenging Fresenius Medical Care Ag & Co. KGaA’s (Fresenius) proposed acquisition of an exclusive sublicense from Luitpold Pharmaceuticals, Inc. (Luitpold), a wholly owned U.S. subsidiary of the Japanese firm Daiichi Sankyo Company, Ltd. Under the sublicense, Fresenius would manufacture and supply the intravenous iron drug Venofer to […]